Prostate Cancer and Prostatic Diseases

Article	Citations
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging	92
Best of 2022 in prostate cancer and prostatic diseases	86
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?	76
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?	69
New BPH therapy classification: what really FITs?	58
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis	58
More evidence that physical activity is beneficial for prostate cancer	55
Sexual outcomes in men who have sex with men who underwent radical prostatectomy	52
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer	49
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States	42
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction	41
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study	38
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study	37
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions	37
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)	36
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro	36
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer	35
Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes	34
Concerns regarding prostate cancer screening guidelines in minority populations	33
Germline alterations among Hispanic men with prostate cancer	32
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches	30
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis	30
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts	29
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations	29
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer	29

Correction: Application of next-generation imaging in biochemically recurrent prostate cancer	29
Incidence of prostate cancer in transgender women in the US: a large database analysis	29
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer	29
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study	28
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients	28
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis	28
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy	27
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions	26
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids	26
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study	26
TRexit is going one step further	26
Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database	25
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms	25
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure	25
The effects of glycemic index on prostate cancer progression in a xenograft mouse model	24
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials	24
Feasibility and safety study of the Flostent™ system (RAPID-I)	24
The evolving clinical use of prostate cancer biomarkers	24
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer	24
“Targeted microwave ablation: another way to kick the can(cer) down the road?”	24
The times have changed. Let the urologists change!	23
Reply to RE: Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?	23
Selective Bone Scan staging for patients with Prostate cancer: do absolute categories really make sense?	23
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)	22
Antimicrobial prophylaxis: To do or not to do? This is the question	22
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy	22
Methodological concerns regarding KEYNOTE-199: immortal time bias and treatment attribution challenges in combination immunotherapy	22
Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	21
Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey	20
Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants	20
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction	20
Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision	20
Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature	20
Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT	20
High GLUT1 membrane expression and low PSMA membrane expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate	20
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study	20
Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics	19
Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases	19
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	19
Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system	19
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK	19
Editorial Expression of Concern: Ethanol promotes cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand through induction of reactive oxygen species in prostate cancer cells	19
Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT	18
Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer	18
Prognostic value of MR visibility/invisibility in men on Active Surveillance	18
Established focal therapy—HIFU, IRE, or cryotherapy—where are we now?—a systematic review and meta-analysis	18
Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis	18
Survivorship in prostate cancer following robotic assisted radical prostatectomy–the time to act is now!	18
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies	18
The role of preoperative prostatic shape in the recovery of urinary continence after robotic radical prostatectomy: a single cohort analysis	18

Association of prostate cancer with human papillomavirus infections: a case-control study	18
A healthy diet, a healthy prostate? A brief commentary on the latest research on diet and prostate cancer	17
The relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy	17
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan	17
Correction: Estimating patient health in prostate cancer treatment counseling	17
Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry	17
Sleep disturbances are underappreciated in prostate cancer survivorship	16
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer	16
Correction: Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”	16
Re: Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis	16
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial	16
Top-down holmium laser enucleation of the prostate (HoLEP) versus traditional HoLEP for the treatment of benign prostatic hyperplasia (BPH): 1-year outcomes of a randomized controlled trial	16
The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study	16
Perioperative outcomes comparing the DaVinci 5 with DaVinci Xi in patients undergoing robotic-assisted radical prostatectomy	16
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients—towards a tumor volume-based risk stratification	16
Risk calculators for the detection of prostate cancer: a systematic review	16
Prevalence and determinants of shared decision-making for PSA testing in the United States	15
Less is more: the “Safety Net Approach” balances precision and safety	15
MRI accuracy for recurrence after partial gland ablation with HIFU for localized prostate cancer. A systematic review and meta-analysis	15
Yoga, benign prostatic hyperplasia and lower urinary tract symptoms: a new path for clinical trials	15
Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy	15
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer	15
Potential miscommunication of risk in American College of Radiology Prostate Imaging and Data System (PIRADS) scores	15
Revisiting ADT in mCRPC: balancing oncologic control and mitochondrial implications	15
Cardiovascular risk in ADT recipients: does the type of ADT matter?	15
Is extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?	14
The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review	14
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey	14
Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscape	14
Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer	14
Characteristics of incidental prostate cancer in the United States	14
Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review	14
Best of 2023 in Prostate Cancer and Prostatic Diseases	13
The impact of race on survival in metastatic prostate cancer: a systematic literature review	13
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed	13
Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?	13
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	13
Negative perceptions of the health system and racial inequities in PSA screening	13
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with doceta	13
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer	13
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.‘s findings	13
Quality of information and appropriateness of ChatGPT outputs for urology patients	12
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomiz	12
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study	12
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations	12
Hyperglycemia and microRNAs in prostate cancer	12
Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only	12
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis	12
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting	12
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer	12
Head-to-head comparison of diagnostic test accuracy between biparametric and multiparametric MRI: an updated systematic review and bivariate meta-analysis	12
The changing face of castrate resistant prostate cancer	12
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes	12
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)	11
Overcoming barriers to prostate cancer genetic testing: who, when, and how	11
Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study	11
NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer	11
Quality of information and appropriateness of Open AI outputs for prostate cancer	11
Biopsy strategies in the era of mpMRI: a comprehensive review	11
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment	11
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	11
Surveillance after Focal Therapy – a Comprehensive Review	11
Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH	11
Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry	11
Prostatic high-resolution micro-ultrasound: an attractive step-forward in the management of prostate cancer patients	11
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer	11
Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?	11
Prostate cancer and prostatic diseases is “Your” journal	10
New robotic platforms for prostate surgery: the future is now	10
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer	10
Best of 2024 in Prostate Cancer and Prostatic diseases	10
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration	10
Brachytherapy monotherapy for favorable and select unfavorable intermediate risk prostate cancer	10
Social determinants of health into evaluations of quality and appropriateness of AI assistant ChatGPT	10
Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”	10
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care	10
MISTs for benign prostatic hyperplasia as first line interventional treatment: Alea iacta est?	10
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study	10
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis	10
The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016	10

15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer

10